Answers are grounded in this paper and cite their sources.
Disturbances in sexual function are a common feature of chronic renal failure. Approximately 50% of uremic men complain of erectile dysfunction while an even greater percentage of both men and women complain of decreased libido and a marked decline in the frequency of intercourse (1,2). The genesis of sexual dysfunction is multifactorial and is primarily organic in origin. In addition to the uremic milieu, peripheral neuropathy, autonomic insufficiency, peripheral vascular disease, and pharmacologic therapy all play an important role in the genesis of this problem. In addition, psychologic and physical stresses are also commonly present in this setting. Sexual Dysfunction in Uremic Men In men with chronic renal failure, disturbances in the pituitary-gonadal axis can be detected with only moderate reductions in the GFR and progressively worsen as the renal failure progresses. These disorders rarely normalize with initiation of hemodialysis or peritoneal dialysis and, in fact, often progress. By comparison, a well-functioning renal transplant is much more likely to restore normal sexual activity, although some features of reproductive function may remain impaired (3). Testicular Function Chronic renal failure is associated with impaired spermatogenesis and testicular damage, often leading to infertility (4). Semen analysis typically shows a decreased volume of ejaculate, either low or complete azoospermia, and a low percentage of motility. These abnormalities are often apparent before the need for dialysis and then deteriorate further once dialytic therapy is initiated. Histologic changes in the testes include evidence of decreased spermatogenic activity with the greatest changes in the hormonally dependent later stages of spermatogenesis. The number of spermatocytes is reduced and there is little evidence of maturation to the stage of mature sperm. In most instances, the number of spermatogonia is normal but on occasion complete aplasia of germinal elements may also be present. Other findings include damage to the seminiferous tubules, interstitial fibrosis, and calcifications. Unlike other causes of severe primary testicular lesions, the Leydig and Sertoli cells show little evidence of hypertrophy or hyperplasia. This later finding suggests a defect in the hormonal regulation of the Leydig and Sertoli cells as might occur with either gonadotropin deficiency or resistance, rather than a cytotoxic effect of uremia where spermatogonia would be most affected (5). The factors responsible for testicular damage in uremia are not well understood. It is possible that plasticizers in dialysis tubing, such as phthalate, may play a role in propagating the abnormalities once patients begin maintenance hemodialysis. Sex Steroids In addition to impaired spermatogenesis, the testes also show evidence of impaired endocrine function. Total and free testosterone levels are typically reduced, although the binding capacity and concentration of sex hormone-binding globulin are normal (6,7,8). Acute stimulation of testosterone secretion with administration of human chorionic gonadotropin (HCG), a compound with luteinizing hormone-like actions, produces only a blunted response in uremic men (9). Lower free testosterone levels and impaired Leydig cell sensitivity to HCG are first detectable with only moderate reductions in the GFR and before basal levels of testosterone fall. Recent studies have shown evidence of a factor in uremic serum capable of blocking the luteinizing hormone receptor, thus providing an explanation for the sluggish response of the Leydig cell to infusion of HCG (10). This blocking activity is inversely correlated with GFR and largely disappears after transplantation. Compared with testosterone, the total plasma estrogen concentration is often elevated in advanced renal failure (8). However, the physiologically important estradiol levels are typically in the normal range. As with the lack of hypertrophy and hyperplasia of Leydig cells, normal levels of estradiol suggest a functional gonadotropin deficiency or resistance in uremia because increased luteinizing hormone levels should enhance the testicular secretion of estradiol (5). Hypothalamic-Pituitary Function The plasma concentration of the pituitary gonadotropin, luteinizing hormone (LH), is elevated in uremic men (8). Elevated levels are found early in renal insufficiency and progressively rise with deteriorating renal function. The excess LH secretion in this setting is thought to result from the diminished release of testosterone from the Leydig cells, since testosterone normally leads to feedback inhibition of LH release. In addition, the metabolic clearance rate of LH is reduced as a result of decreased renal clearance. The increase in serum LH is variable and modest when compared to that observed in castrate nonuremic subjects. The lack of a more robust response of LH to low levels of circulating testosterone suggests a derangement in the central regulation of gonadotropin release. Infusion of gonadotropin-releasing hormone (GnRH) increases LH levels to the same degree as in healthy subjects; however, the peak value and return to baseline may be delayed (11,12). Since the kidney contributes importantly to the clearance of GnRH and LH, decreased metabolism of these hormones may explain the observed variations. The abnormal LH response to GnRH precedes and is not corrected by dialytic therapy. By contrast, renal transplantation returns the response of gonadotropins back to normal. In addition to decreased metabolism, subtle disturbances in LH secretion have also been described. Under normal circumstances, LH is secreted in a pulsatile manner. In uremic subjects, the number of secretory bursts remains normal but the amount of LH released per secretory burst is reduced (13). It is not known whether this decrease in amplitude is the result of a change in the pattern of GnRH release from the hypothalamus or a change in the responsiveness of the pituitary. In either case, the secretory pattern of LH returns to normal with the placement of a well-functioning allograft. Follicle-stimulating hormone (FSH) secretion is also increased in men with chronic renal failure, although to a more variable degree such that the LH/FSH ratio is typically increased. FSH release by the pituitary normally responds to feedback inhibition by a peptide product of the Sertoli cells called inhibin. The plasma FSH concentration tends to be highest in those uremic patients with the most severe damage to seminiferous tubules and presumably the lowest levels of inhibin. It has been suggested that increased FSH levels may portend a poor prognosis for recovery of spermatogenic function after renal transplantation (4,14). Clomiphene is a compound that acts by competing with estrogen or testosterone for receptors at the level of the hypothalamus and prevents the negative feedback of gonadal steroids on the release of GnRH and subsequently the release of pituitary gonadotropins. When administered to chronic renal failure patients, there is an appropriate rise in the levels of both LH and FSH, suggesting that the negative feedback control of testosterone on the hypothalamus is intact and that the storage and release of gonadotropins by the pituitary is normal (8). In summary, a number of observations suggest that gonadal failure is an important consequence of chronic renal failure. The finding that LH levels are typically increased is consistent with the presence of testicular damage. However, the lack of Leydig cell hypertrophy and normal estradiol levels also raise the possibility of functional hypogonadism. The finding that LH levels are only modestly increased in chronic renal failure suggests a diminished response of the hypothalamic-pituitary axis to lowered testosterone levels and impaired regulation of gonadotropin secretion. One explanation for the blunted rise in LH in response to low levels of testosterone is that the hypothalamic-pituitary axis in chronic renal failure is reset in such a way that it is more sensitive to the negative feedback inhibition of testosterone. In this manner, the axis begins to assume a similar characteristic as seen in the prepubertal state where there is extreme sensitivity to the inhibitory effect of gonadal steroids (5). Prolactin Metabolism Elevated plasma prolactin levels are commonly found in dialyzed men (15). Increased production is primarily responsible, since the kidney plays little, if any, role in the catabolism of this hormone. Prolactin release is normally under dopaminergic inhibitory control. Its secretion in chronic renal failure, however, appears autonomous and resistant to stimulatory or suppressive maneuvers. As an example, dopamine infusion or the administration of oral L-dopa fails to decrease basal prolactin levels. On the other hand, procedures that normally increase prolactin secretion such as arginine infusion, insulin-induced hypoglycemia, or thyrotropin-releasing hormone infusion elicit no response or only a blunted response. Again, these abnormalities resolve after a successful renal transplant. Increased prolactin secretion in chronic renal failure may be related in part to the development of secondary hyperparathyroidism. An infusion of parathyroid hormone (PTH) in healthy men enhances prolactin release, a response that can be suppressed by the administration of L-dopa (16). Furthermore, partial inhibition of PTH release by the administration of calcitriol led in one study to an elevation in plasma testosterone levels, a reduction in plasma gonadotropin concentrations, and improved sexual function (17). However, this benefit could not be confirmed in a controlled trial of calcitriol therapy (18). Depletion of total body zinc stores may also play an etiologic role in uremic hyperprolactinemia (19). The clinical significance of enhanced prolactin release in uremic men is incompletely understood. Extreme hyperprolactinemia is associated with infertility, loss of libido, low circulating testosterone levels, and inappropriately low LH levels in men with normal renal function. These observations led to the evaluation of therapy with bromocryptine, which reduces prolactin secretion. Although it can lower prolactin levels to near normal in men with advanced renal disease, there has been an inconsistent effect on sexual potency and libido (15). In addition, a high incidence of side effects may be seen, particularly hypotension. Gynecomastia Gynecomastia occurs in approximately 30% of men on maintenance hemodialysis. This problem most often develops during the initial months of dialysis and then tends to regress as dialysis continues. The pathogenesis of gynecomastia in this setting is unclear. Although elevated prolactin levels and an increased estrogen-to-androgen ratio seem attractive possibilities, most data fail to support a primary role for abnormal hormonal function. Alternatively, a mechanism similar to that responsible for gynecomastia following refeeding of malnourished patients may be involved. Evaluation of Sexual Dysfunction in Uremic Men Sexual dysfunction can be manifest in several ways in uremic men. Perhaps the most common complaint the physician must address is that of impotence (Table 1). In evaluating and ultimately treating the impotent renal failure patient, one must not only consider disturbances in the hypothalamic-pituitary-gonadal axis discussed above, but also abnormalities in the sympathetic nervous system and derangements in the arterial supply or venous drainage of the penis. In addition, the psychologic effects of a chronic illness and lifestyle limitations may have a negative impact on sexual function.Table 1: Factors involved in the pathogenesis of impotence in uremic menaA through history and physical can provide useful information during the initial evaluation of a patient with impotence. A history of normal erectile function before the development of renal failure suggests a secondary cause of impotence. Symptoms or physical findings of a neuropathy as in a patient with a neurogenic bladder would indicate a neurologic etiology. Similarly, symptoms or signs of peripheral vascular disease may be a clue to the presence of vascular obstruction to penile blood flow. One should look for the presence of secondary sexual characteristics, such as facial, axillary, and pubic hair. The lack of these findings and the presence of small soft testicles suggest primary or secondary hypogonadism as the cause of the impotence. Neurogenic and vascular causes are more likely to be associated with normalsized testicles. Even when the history and physical point to a specific abnormality, one must also consider that an individual patient may have more than one factor responsible for the erectile dysfunction and other causes may need to be ultimately evaluated. A review of the patient's medications may reveal a drug that could be responsible for impairing sexual function. Antihypertensive medications are common offenders, with centrally acting agents and beta blockers being the most commonly implicated agents in causing impotence. The angiotensin-converting enzyme inhibitors or angiotensin receptor blockers are associated with a lower incidence of impotence and represent a useful alternative in renal failure patients with hypertension. Other drugs commonly implicated include cimetidine, phenothiazines, tricyclic antidepressants, and metoclopramide. If the history and physical examination reveal no obvious cause, then a psychologic cause of erectile dysfunction may need to be considered. Testing for the presence of nocturnal penile tumescence (NPT) has been done in some centers as a means to discriminate between a psychologic and organic cause of impotence. The basis for this test is that during the rapid eye movement stage of sleep, males normally have an erection. The assumption is that a man with a psychologic cause of impotence would still experience erections while asleep, whereas the absence of an adequate erection would make an organic cause more likely. If a patient is found to have nocturnal erections, then psychologic testing and evaluation is indicated. It should be noted that NPT testing is not infallible and that if a patient has a normal test and no psychologic cause is found then evaluation for an organic cause should still be may sexual function and to reduced libido and decreased frequency of As a it has been suggested that may play a role in the genesis of sexual dysfunction in chronic renal failure this have found no between the presence or absence of and of sexual function such as frequency of intercourse or to an erection as by NPT testing In a more a of peritoneal dialysis patients that both men and women and found that of patients intercourse than or to per and intercourse more than per In this psychologic that the patients intercourse more and and of at a level that lower than that of the other may be as a cause of sexual dysfunction in both uremic men and It is also likely that symptoms of and associated with the of renal disease are also factors in this problem are that may in the between a neurogenic and a vascular cause of impotence. to a vascular of impotence include studies to penile blood of penile and penile Neurogenic impotence is suggested by a of the or the presence of a neurogenic the of to in a such are for may be for placement of a penile As discussed hormonal abnormalities are detected in chronic renal failure that are useful in the evaluation of an organic cause of impotence include of serum LH, FSH, testosterone, and prolactin levels. It should be noted that only a small percentage of uremic patients have prolactin levels studies of the hypothalamic-pituitary should be in patients with levels of greater to the presence of a or of Sexual Dysfunction in Uremic Men The of sexual dysfunction in uremic men is of a 1). One to of dialysis and adequate of human has been shown to enhance sexual function in chronic renal failure. It is likely that the associated in that with the of plays an important role in this response. In some therapy has been to cause of the pituitary gonadal feedback mechanism with reduced plasma of LH and FSH and increases in plasma testosterone levels in elevated plasma prolactin levels have also been noted It is as to whether these changes are the result of of the or a effect of As the degree of secondary with may be of benefit in prolactin levels and sexual function in some to sexual dysfunction in uremic with normal NPT testing should be to whether there is a psychologic to the impotence. If a problem is found then a trial of is The of medications in chronic renal failure patients with sexual dysfunction has not been well In patients with a neurogenic or vascular cause of include of of or placement of a penile is typically in patients fail the the of for the of men with erectile this as the therapy for patients with or neurogenic causes of impotence. have been no studies to the and of in chronic renal failure However, the drug appears in such Since the of patients renal therapy in the are it is that a controlled trial found that both and well in men with erectile dysfunction than of the patients in this study to have either a neurogenic or vascular of erectile patients with renal disease experience a similar benefit is not It should be that is in patients are organic should also be when this to patients with known In patients with low circulating levels of testosterone, the in clinical in other of gonadal failure. By contrast, administration of testosterone to uremic men fails to restore libido or increased testosterone levels and reduced release of LH and FSH In a of dialysis patients with administration of testosterone sexual function in only patients In those patients to of a tumescence corrected penile erection dysfunction in the of In a patient primary complaint is decreased libido, a trial of testosterone may be In administration of has also been to cause a of plasma testosterone levels associated with some in sexual function. found to have increased circulating levels of prolactin may benefit from a trial of This is a dopaminergic that has shown some in sexual function presumably by elevated prolactin levels. However, has been by a high frequency of side Other dopaminergic such as and seem to be but have only been in small deficiency has also been suggested as a cause of gonadal failure. Uremic patients are often in to reduced zinc possible of zinc by dialysis In a controlled zinc in increases in the plasma testosterone concentration and as well as in LH and FSH levels compared with a control libido, and frequency of also improved in those patients It is possible that of total body zinc may also be in uremic hyperprolactinemia (19). the data suggest that the administration of zinc in a man is a Sexual Dysfunction in Uremic Disturbances in and are commonly in women with chronic renal failure, leading to by the the patient renal The typically remains with after the initiation of maintenance although normal is in some women In leading to blood loss and increased The in uremic women is with affected patients being on chronic dialysis also to complain of decreased libido and reduced to can rarely occur in advanced renal failure, but is increased. renal function is present in the that can be to The of in chronic renal insufficiency has been The normal is a or and a or secretory maturation and secretion of the pituitary gonadotropins. FSH secretion negative with hormone levels as the plasma estrogen concentration In contrast, LH secretion is suppressed by low of estrogen but feedback control in response to a and elevation of high levels of estradiol in the a elevation in LH which is responsible for levels increase to production by the is responsible for the of the the Disturbances in Uremic of suggests that are the in uremic women example, show an absence of and there is a failure to increase basal body at the when would be In addition, the peak in LH and estradiol is The failure of LH to rise in part a in the estradiol feedback since the administration of estrogen to the in estradiol fails to LH release In contrast, feedback inhibition of gonadotropin release by low of estradiol remains This can be by the of the to enhance LH and FSH secretion. It remains whether the disturbances in gonadotropin production in the hypothalamus impaired production of or in the pituitary It is for example, that are involved. levels are increased in chronic renal failure primarily to reduced renal and can by the release of Prolactin and with chronic renal failure commonly have elevated circulating prolactin levels. As in men with chronic renal failure, the of prolactin in this setting appears to be as it is resistant to to or release. It has been suggested that the elevated prolactin levels may hypothalamic-pituitary function and to sexual dysfunction and in these It is of in this that nonuremic women with pituitary commonly present with and low circulating gonadotropin levels. However, uremic women with rarely normal and to complain of of the plasma prolactin concentration factors other than hyperprolactinemia must be important in this setting. Disturbances in Uremic uremic women have gonadotropin levels as high as those seen in nonuremic women of similar This is consistent with the finding in women that negative feedback inhibition of estrogen on LH and FSH release is intact in However, the at which begins in chronic renal failure tends to be decreased when compared to healthy The high frequency of leads to lack of of the and failure of secretion. is responsible for the the lack of is associated with patients to administration of a during the of the be On the other hand, can to the of chronic renal disease, particularly in those patients with In this administration of a during the flow. a patient may for It is not known whether the absence of in women with chronic renal failure to the development of hyperplasia and possible Since these patients are often there is no of the effect of estrogen by the release of It is that women with chronic renal failure be by a it may be in at some patients to a several per to the by estrogen release to sexual dysfunction in uremic can rarely occur in women on chronic of as a should be In comparison, the abnormalities in can be and successful in women with a well-functioning renal transplant. Uremic women are normally should be to control. the therapy of decreased libido and sexual function in uremic women are hemodialysis patients may have low estradiol levels that can to and and result in during patients may benefit from estrogen therapy or testosterone may be in sexual but is rarely secondary to therapy in patients may in sexual function but has not been well may sexual function in those patients with low circulating estradiol levels. transplantation is the most means to restore normal sexual in women with chronic renal failure In summary, sexual dysfunction is a common finding in both men and women with chronic renal failure. disturbances include erectile dysfunction in abnormalities in and decreased libido and in both These abnormalities are primarily organic in and are related to uremia as well as the other that the chronic renal failure and factors related to the presence of a chronic disease are also Disturbances in the hypothalamic-pituitary-gonadal axis can be detected before the need for dialysis but to worsen once dialytic therapy is initiated. gonadal function is in uremic whereas the disturbances in the hypothalamic-pituitary axis are more By contrast, central disturbances are more in uremic is the of with and the degree of secondary with has the therapy in the of impotence. In the man only complaint is decreased libido, testosterone may be of is in uremic women to of estrogen Uremic women should be while on transplantation is the most means of normal sexual function in both men and women with chronic renal failure.
No takes yet. Share an insight, caveat, or question.
Biff F. Palmer (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: